Replimune Group, Inc. (REPL): EPS (Basic)

Annual figures by period end, from SEC filings.

-$3.38

Year ended 2026-03-31

2021-03-31 EPS (Basic) (USD per share) 2026-03-31

Period ended	EPS (Basic)	Change YoY	Source filing
2026-03-31	-$3.38	n/m	2026-06-29, From 2025-04-01
2025-03-31	-$3.07	n/m	2026-06-29, From 2024-04-01
2024-03-31	-$3.24	n/m	2025-05-22, From 2023-04-01
2023-03-31	-$2.99	n/m	2024-05-16, From 2022-04-01
2022-03-31	-$2.26	n/m	2023-05-18, From 2021-04-01
2021-03-31	-$1.75	n/a	2022-05-19, From 2020-04-01

EPS (Basic) at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	EPS (Basic)	Change YoY
Replimune Group, Inc. (REPL)	2026-03-31	-$3.38	n/m
Prime Medicine, Inc. (PRME)	2025-12-31	-$1.35	n/m
Taysha Gene Therapies, Inc. (TSHA)	2025-12-31	-$0.34	n/m
Fate Therapeutics Inc (FATE)	2025-12-31	-$1.15	n/m
Kodiak Sciences Inc. (KOD)	2025-12-31	-$4.32	n/m
C4 Therapeutics, Inc. (CCCC)	2025-12-31	-$1.27	n/m
LENZ Therapeutics, Inc. (LENZ)	2025-12-31	-$2.85	n/m
Scilex Holding Co (SCLX)	2025-12-31	-$36.48	n/m
Kyverna Therapeutics, Inc. (KYTX)	2025-12-31	-$3.64	n/m

Compare REPL, PRME, TSHA, FATE side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗